| Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Cholangitis, Sclerosing | 7 | 2023 | 160 | 2.020 |
Why?
|
| Liver Cirrhosis, Biliary | 4 | 2023 | 98 | 1.090 |
Why?
|
| Cholangitis | 4 | 2022 | 108 | 0.940 |
Why?
|
| Bile Duct Neoplasms | 2 | 2021 | 567 | 0.770 |
Why?
|
| Cholangiocarcinoma | 2 | 2021 | 516 | 0.760 |
Why?
|
| Bezafibrate | 1 | 2019 | 14 | 0.700 |
Why?
|
| Cholestasis | 3 | 2022 | 378 | 0.610 |
Why?
|
| Liver Diseases | 6 | 2020 | 1253 | 0.570 |
Why?
|
| Ursodeoxycholic Acid | 4 | 2023 | 72 | 0.520 |
Why?
|
| Bile Ducts, Intrahepatic | 2 | 2021 | 295 | 0.460 |
Why?
|
| Antimony Potassium Tartrate | 1 | 2012 | 3 | 0.440 |
Why?
|
| Liver | 10 | 2021 | 7475 | 0.430 |
Why?
|
| Liver Function Tests | 4 | 2020 | 528 | 0.390 |
Why?
|
| Liver Transplantation | 9 | 2023 | 2119 | 0.390 |
Why?
|
| Poisoning | 1 | 2012 | 249 | 0.380 |
Why?
|
| Hepatitis, Autoimmune | 1 | 2012 | 141 | 0.360 |
Why?
|
| Bile Acids and Salts | 3 | 2007 | 368 | 0.340 |
Why?
|
| Fatty Liver | 3 | 2023 | 727 | 0.300 |
Why?
|
| Bile Duct Diseases | 1 | 2006 | 100 | 0.270 |
Why?
|
| Carcinoma, Hepatocellular | 3 | 2014 | 2214 | 0.260 |
Why?
|
| alpha 1-Antitrypsin Deficiency | 1 | 2005 | 107 | 0.250 |
Why?
|
| Genome-Wide Association Study | 1 | 2023 | 12262 | 0.240 |
Why?
|
| Cholangiopancreatography, Endoscopic Retrograde | 1 | 2007 | 504 | 0.240 |
Why?
|
| Autoimmune Diseases | 5 | 2018 | 2134 | 0.240 |
Why?
|
| Hepatitis B | 1 | 2009 | 695 | 0.230 |
Why?
|
| Liver Abscess | 1 | 2003 | 82 | 0.210 |
Why?
|
| Hepatopulmonary Syndrome | 1 | 2021 | 20 | 0.200 |
Why?
|
| Portasystemic Shunt, Transjugular Intrahepatic | 2 | 2019 | 95 | 0.200 |
Why?
|
| Klebsiella Infections | 1 | 2003 | 138 | 0.200 |
Why?
|
| Liver Neoplasms | 3 | 2014 | 4253 | 0.200 |
Why?
|
| Alagille Syndrome | 1 | 2001 | 35 | 0.200 |
Why?
|
| Antiviral Agents | 2 | 2014 | 2987 | 0.190 |
Why?
|
| Klebsiella pneumoniae | 1 | 2003 | 251 | 0.190 |
Why?
|
| Dyskeratosis Congenita | 1 | 2021 | 72 | 0.190 |
Why?
|
| Colonic Pseudo-Obstruction | 1 | 2000 | 6 | 0.190 |
Why?
|
| Alkaline Phosphatase | 2 | 2023 | 867 | 0.190 |
Why?
|
| gamma-Glutamyltransferase | 1 | 2000 | 134 | 0.180 |
Why?
|
| Transaminases | 1 | 2000 | 200 | 0.170 |
Why?
|
| Liver Cirrhosis | 4 | 2023 | 1862 | 0.160 |
Why?
|
| Hepatitis C, Chronic | 2 | 2014 | 1031 | 0.160 |
Why?
|
| Pancreatitis, Acute Necrotizing | 1 | 2000 | 172 | 0.160 |
Why?
|
| Gastrointestinal Hemorrhage | 3 | 2006 | 1131 | 0.160 |
Why?
|
| Constriction, Pathologic | 1 | 2021 | 1107 | 0.160 |
Why?
|
| Hepatitis, Chronic | 1 | 1997 | 52 | 0.150 |
Why?
|
| PPAR alpha | 1 | 2019 | 197 | 0.150 |
Why?
|
| Liver Failure, Acute | 2 | 2012 | 165 | 0.150 |
Why?
|
| Chenodeoxycholic Acid | 1 | 2017 | 34 | 0.150 |
Why?
|
| Colonic Polyps | 1 | 2001 | 542 | 0.140 |
Why?
|
| Neoplasm Recurrence, Local | 1 | 2014 | 9240 | 0.140 |
Why?
|
| Mass Screening | 2 | 2009 | 5253 | 0.140 |
Why?
|
| In Situ Hybridization, Fluorescence | 1 | 2021 | 2649 | 0.130 |
Why?
|
| Humans | 52 | 2023 | 744366 | 0.130 |
Why?
|
| Azathioprine | 1 | 1996 | 354 | 0.120 |
Why?
|
| Consensus | 2 | 2020 | 2960 | 0.120 |
Why?
|
| Hepatitis | 1 | 1996 | 227 | 0.120 |
Why?
|
| Elasticity Imaging Techniques | 1 | 2018 | 388 | 0.110 |
Why?
|
| Biological Transport | 2 | 2007 | 2120 | 0.100 |
Why?
|
| Pruritus | 2 | 2023 | 361 | 0.100 |
Why?
|
| Drug Eruptions | 1 | 2014 | 297 | 0.100 |
Why?
|
| Biliary Tract | 1 | 2011 | 134 | 0.090 |
Why?
|
| Tamoxifen | 1 | 1995 | 981 | 0.090 |
Why?
|
| Autoantibodies | 3 | 2012 | 2036 | 0.090 |
Why?
|
| Syndrome | 2 | 2007 | 3252 | 0.090 |
Why?
|
| Referral and Consultation | 2 | 2020 | 3531 | 0.090 |
Why?
|
| High-Throughput Nucleotide Sequencing | 1 | 2021 | 3595 | 0.080 |
Why?
|
| Vomiting | 1 | 2012 | 637 | 0.080 |
Why?
|
| Endotoxins | 1 | 2011 | 527 | 0.080 |
Why?
|
| Jaundice | 1 | 2009 | 89 | 0.080 |
Why?
|
| Genotype | 1 | 2023 | 12952 | 0.080 |
Why?
|
| Oligopeptides | 1 | 2014 | 1189 | 0.080 |
Why?
|
| Glucocorticoids | 2 | 1997 | 2108 | 0.080 |
Why?
|
| Practice Guidelines as Topic | 2 | 2020 | 7282 | 0.080 |
Why?
|
| Motion Sickness | 1 | 1988 | 35 | 0.080 |
Why?
|
| Hepatitis B Surface Antigens | 1 | 2009 | 305 | 0.080 |
Why?
|
| Middle Aged | 25 | 2020 | 213390 | 0.080 |
Why?
|
| Cholangiography | 1 | 2008 | 189 | 0.080 |
Why?
|
| Audiovisual Aids | 1 | 1988 | 92 | 0.080 |
Why?
|
| Magnetic Resonance Imaging | 1 | 2014 | 35425 | 0.070 |
Why?
|
| Critical Care | 1 | 2000 | 2647 | 0.070 |
Why?
|
| Immunoglobulin G | 2 | 2009 | 4561 | 0.070 |
Why?
|
| Abdominal Pain | 1 | 1993 | 1064 | 0.070 |
Why?
|
| Multiple Organ Failure | 1 | 2009 | 389 | 0.070 |
Why?
|
| Paraproteinemias | 1 | 2009 | 246 | 0.070 |
Why?
|
| Clinical Laboratory Techniques | 1 | 2012 | 738 | 0.070 |
Why?
|
| Male | 26 | 2020 | 350115 | 0.070 |
Why?
|
| Mesenteric Veins | 1 | 2006 | 89 | 0.070 |
Why?
|
| Female | 26 | 2021 | 380193 | 0.070 |
Why?
|
| Metabolism, Inborn Errors | 1 | 2008 | 288 | 0.070 |
Why?
|
| Hepatitis B virus | 1 | 2009 | 513 | 0.070 |
Why?
|
| Biliary Atresia | 1 | 2005 | 73 | 0.060 |
Why?
|
| Tissue Donors | 3 | 2020 | 2241 | 0.060 |
Why?
|
| Varicose Veins | 1 | 2006 | 154 | 0.060 |
Why?
|
| Adult | 20 | 2020 | 214052 | 0.060 |
Why?
|
| Liver, Artificial | 1 | 2004 | 56 | 0.060 |
Why?
|
| Cost-Benefit Analysis | 1 | 2017 | 5388 | 0.060 |
Why?
|
| Cholagogues and Choleretics | 1 | 2023 | 32 | 0.060 |
Why?
|
| Morbidity | 1 | 2009 | 1768 | 0.060 |
Why?
|
| Cadaver | 2 | 2004 | 1337 | 0.060 |
Why?
|
| Diagnosis, Differential | 4 | 2012 | 12961 | 0.060 |
Why?
|
| Immunosuppressive Agents | 2 | 2015 | 4153 | 0.060 |
Why?
|
| Renal Dialysis | 1 | 2012 | 1783 | 0.050 |
Why?
|
| ATP-Binding Cassette Transporters | 1 | 2006 | 560 | 0.050 |
Why?
|
| Esophageal and Gastric Varices | 2 | 2006 | 207 | 0.050 |
Why?
|
| Cholesterol, LDL | 1 | 2012 | 2355 | 0.050 |
Why?
|
| Pregnancy Complications | 3 | 2006 | 2861 | 0.050 |
Why?
|
| Pancreatitis | 1 | 2009 | 1092 | 0.050 |
Why?
|
| Coronavirus Infections | 1 | 2020 | 3135 | 0.050 |
Why?
|
| Pneumonia, Viral | 1 | 2020 | 3242 | 0.050 |
Why?
|
| Acetates | 1 | 2023 | 311 | 0.050 |
Why?
|
| Prospective Studies | 4 | 2021 | 53290 | 0.050 |
Why?
|
| Prognosis | 4 | 2020 | 29060 | 0.050 |
Why?
|
| Heterozygote | 2 | 2005 | 2804 | 0.050 |
Why?
|
| Intestinal Mucosa | 1 | 2011 | 3037 | 0.050 |
Why?
|
| Intestine, Small | 1 | 2006 | 1240 | 0.040 |
Why?
|
| Endoscopy, Gastrointestinal | 1 | 2006 | 868 | 0.040 |
Why?
|
| Remission Induction | 2 | 2015 | 2385 | 0.040 |
Why?
|
| Hypertension, Portal | 1 | 2002 | 220 | 0.040 |
Why?
|
| Immunohistochemistry | 4 | 2017 | 11366 | 0.040 |
Why?
|
| Transforming Growth Factor beta1 | 1 | 2023 | 644 | 0.040 |
Why?
|
| Immunity, Innate | 1 | 2011 | 2962 | 0.040 |
Why?
|
| Epithelial Cells | 1 | 2011 | 3690 | 0.040 |
Why?
|
| Pericardium | 1 | 2023 | 667 | 0.040 |
Why?
|
| Exercise Tolerance | 1 | 2004 | 768 | 0.040 |
Why?
|
| Antibodies, Monoclonal | 1 | 2015 | 9274 | 0.040 |
Why?
|
| Biopsy, Needle | 2 | 2017 | 1641 | 0.040 |
Why?
|
| gamma-Globulins | 1 | 1997 | 124 | 0.040 |
Why?
|
| Predictive Value of Tests | 4 | 2020 | 15078 | 0.040 |
Why?
|
| Inflammatory Bowel Diseases | 1 | 2012 | 2428 | 0.040 |
Why?
|
| Echocardiography, Transesophageal | 1 | 2023 | 1133 | 0.040 |
Why?
|
| Decision Support Techniques | 2 | 2004 | 1956 | 0.040 |
Why?
|
| Receptors, Cholecystokinin | 1 | 1996 | 18 | 0.040 |
Why?
|
| Gastrins | 1 | 1996 | 81 | 0.040 |
Why?
|
| Tissue and Organ Procurement | 1 | 2004 | 896 | 0.040 |
Why?
|
| Osteoporosis | 1 | 2006 | 1579 | 0.030 |
Why?
|
| Hemochromatosis | 1 | 1997 | 184 | 0.030 |
Why?
|
| Severity of Illness Index | 3 | 2019 | 15535 | 0.030 |
Why?
|
| Treatment Outcome | 7 | 2023 | 63107 | 0.030 |
Why?
|
| Pilot Projects | 2 | 2019 | 8319 | 0.030 |
Why?
|
| Drug Interactions | 1 | 2020 | 1460 | 0.030 |
Why?
|
| Time | 1 | 2017 | 542 | 0.030 |
Why?
|
| Ultrasonography | 1 | 2008 | 5984 | 0.030 |
Why?
|
| Pregnancy | 3 | 2006 | 29144 | 0.030 |
Why?
|
| Biopsy | 2 | 2015 | 6755 | 0.030 |
Why?
|
| Observer Variation | 1 | 2020 | 2593 | 0.030 |
Why?
|
| North America | 1 | 2017 | 1249 | 0.030 |
Why?
|
| Gastroenterology | 1 | 2020 | 538 | 0.030 |
Why?
|
| Disease Progression | 2 | 2023 | 13286 | 0.030 |
Why?
|
| Occupational Health | 1 | 2020 | 808 | 0.030 |
Why?
|
| Sodium | 1 | 2019 | 1622 | 0.030 |
Why?
|
| Diagnostic Imaging | 1 | 2008 | 3508 | 0.030 |
Why?
|
| Hemoglobins | 1 | 2019 | 1532 | 0.030 |
Why?
|
| Abortion, Habitual | 1 | 1993 | 70 | 0.030 |
Why?
|
| Regression Analysis | 2 | 2019 | 6459 | 0.030 |
Why?
|
| Antineoplastic Agents | 1 | 2015 | 13693 | 0.030 |
Why?
|
| Colchicine | 1 | 1993 | 244 | 0.030 |
Why?
|
| Colonoscopy | 1 | 2019 | 1367 | 0.020 |
Why?
|
| Aged | 10 | 2019 | 163288 | 0.020 |
Why?
|
| Echocardiography | 1 | 2023 | 5099 | 0.020 |
Why?
|
| Risk Factors | 3 | 2020 | 72296 | 0.020 |
Why?
|
| Receptors, Pattern Recognition | 1 | 2011 | 79 | 0.020 |
Why?
|
| Evidence-Based Medicine | 1 | 2022 | 3611 | 0.020 |
Why?
|
| Quality-Adjusted Life Years | 1 | 2017 | 1683 | 0.020 |
Why?
|
| Blotting, Northern | 1 | 2011 | 1581 | 0.020 |
Why?
|
| Markov Chains | 2 | 2004 | 969 | 0.020 |
Why?
|
| Acute Disease | 1 | 2000 | 7147 | 0.020 |
Why?
|
| Iron | 1 | 1997 | 1774 | 0.020 |
Why?
|
| Cholangiopancreatography, Magnetic Resonance | 1 | 2009 | 101 | 0.020 |
Why?
|
| Young Adult | 3 | 2021 | 56429 | 0.020 |
Why?
|
| Immunoprecipitation | 1 | 2011 | 906 | 0.020 |
Why?
|
| Drug Administration Schedule | 1 | 2017 | 4933 | 0.020 |
Why?
|
| Interleukin-8 | 1 | 2011 | 690 | 0.020 |
Why?
|
| Signal Transduction | 1 | 2011 | 23404 | 0.020 |
Why?
|
| Exercise | 1 | 2004 | 5615 | 0.020 |
Why?
|
| Gene Expression Profiling | 1 | 2023 | 9445 | 0.020 |
Why?
|
| Survival Analysis | 3 | 2004 | 10252 | 0.020 |
Why?
|
| Hemorrhage | 1 | 2019 | 3461 | 0.020 |
Why?
|
| Risk Assessment | 2 | 2019 | 23336 | 0.020 |
Why?
|
| Liver Cirrhosis, Alcoholic | 1 | 2006 | 65 | 0.020 |
Why?
|
| Attitude of Health Personnel | 1 | 2020 | 3841 | 0.020 |
Why?
|
| Video-Assisted Surgery | 1 | 2006 | 51 | 0.020 |
Why?
|
| Boston | 1 | 2019 | 9312 | 0.020 |
Why?
|
| Animals | 4 | 2007 | 168768 | 0.020 |
Why?
|
| Plasma Cells | 1 | 2009 | 591 | 0.020 |
Why?
|
| Hepatectomy | 1 | 2009 | 550 | 0.020 |
Why?
|
| Comorbidity | 1 | 2020 | 10388 | 0.020 |
Why?
|
| Health Knowledge, Attitudes, Practice | 1 | 2020 | 3922 | 0.020 |
Why?
|
| Multivariate Analysis | 1 | 2019 | 12244 | 0.020 |
Why?
|
| Phlebography | 1 | 2006 | 333 | 0.020 |
Why?
|
| Immunophenotyping | 1 | 2009 | 1880 | 0.020 |
Why?
|
| Dose-Response Relationship, Drug | 1 | 2017 | 10943 | 0.020 |
Why?
|
| Models, Statistical | 1 | 2019 | 5101 | 0.020 |
Why?
|
| Enzyme-Linked Immunosorbent Assay | 1 | 2011 | 3873 | 0.010 |
Why?
|
| Dermatology | 1 | 2014 | 872 | 0.010 |
Why?
|
| Steroids | 1 | 2009 | 930 | 0.010 |
Why?
|
| Reverse Transcriptase Polymerase Chain Reaction | 1 | 2011 | 4751 | 0.010 |
Why?
|
| Portal Vein | 1 | 2006 | 437 | 0.010 |
Why?
|
| Blotting, Western | 1 | 2011 | 5181 | 0.010 |
Why?
|
| Heart Function Tests | 1 | 2004 | 328 | 0.010 |
Why?
|
| Microscopy | 1 | 1988 | 902 | 0.010 |
Why?
|
| Reproducibility of Results | 2 | 2018 | 19905 | 0.010 |
Why?
|
| Sensitivity and Specificity | 1 | 2018 | 14723 | 0.010 |
Why?
|
| NF-kappa B | 1 | 2011 | 2499 | 0.010 |
Why?
|
| United States | 2 | 2009 | 69872 | 0.010 |
Why?
|
| Bilirubin | 1 | 2004 | 425 | 0.010 |
Why?
|
| Sigmoid Neoplasms | 1 | 2002 | 51 | 0.010 |
Why?
|
| Age Factors | 1 | 2019 | 18373 | 0.010 |
Why?
|
| Patient Selection | 2 | 2004 | 4216 | 0.010 |
Why?
|
| Mutation | 1 | 2006 | 29786 | 0.010 |
Why?
|
| Flow Cytometry | 1 | 2011 | 5974 | 0.010 |
Why?
|
| Prevalence | 1 | 2017 | 15221 | 0.010 |
Why?
|
| Pandemics | 1 | 2020 | 8385 | 0.010 |
Why?
|
| Internship and Residency | 1 | 2020 | 5791 | 0.010 |
Why?
|
| Tumor Necrosis Factor-alpha | 1 | 2011 | 4424 | 0.010 |
Why?
|
| Respiratory Function Tests | 1 | 2004 | 1617 | 0.010 |
Why?
|
| Monte Carlo Method | 1 | 2004 | 1254 | 0.010 |
Why?
|
| Aged, 80 and over | 2 | 2015 | 57776 | 0.010 |
Why?
|
| Living Donors | 1 | 2001 | 621 | 0.010 |
Why?
|
| Adolescent | 3 | 2004 | 85779 | 0.010 |
Why?
|
| Cross-Sectional Studies | 1 | 2017 | 25039 | 0.010 |
Why?
|
| Transferrin | 1 | 1997 | 295 | 0.010 |
Why?
|
| Models, Biological | 1 | 1993 | 9584 | 0.010 |
Why?
|
| Equipment Design | 1 | 2004 | 3582 | 0.010 |
Why?
|
| Follow-Up Studies | 1 | 2017 | 39052 | 0.010 |
Why?
|
| Intraoperative Complications | 1 | 2002 | 1198 | 0.010 |
Why?
|
| Life Expectancy | 1 | 2001 | 1184 | 0.010 |
Why?
|
| Ferritins | 1 | 1997 | 590 | 0.010 |
Why?
|
| Cohort Studies | 1 | 2017 | 40559 | 0.010 |
Why?
|
| Time Factors | 1 | 2015 | 40075 | 0.010 |
Why?
|
| Danazol | 1 | 1993 | 42 | 0.010 |
Why?
|
| Antibodies, Antiphospholipid | 1 | 1993 | 69 | 0.010 |
Why?
|
| Homozygote | 1 | 1997 | 1787 | 0.010 |
Why?
|
| Xenopus laevis | 1 | 1996 | 957 | 0.010 |
Why?
|
| Primary Ovarian Insufficiency | 1 | 1993 | 115 | 0.010 |
Why?
|
| Antibodies, Antinuclear | 1 | 1993 | 326 | 0.010 |
Why?
|
| Antiphospholipid Syndrome | 1 | 1993 | 173 | 0.010 |
Why?
|
| Retrospective Studies | 2 | 2012 | 77460 | 0.010 |
Why?
|
| Neoplasm Staging | 1 | 2004 | 11031 | 0.010 |
Why?
|
| Proportional Hazards Models | 1 | 2004 | 12356 | 0.010 |
Why?
|
| Fetal Growth Retardation | 1 | 1993 | 570 | 0.010 |
Why?
|
| Isoantibodies | 1 | 1993 | 679 | 0.010 |
Why?
|
| Spermatozoa | 1 | 1993 | 625 | 0.010 |
Why?
|
| Immunoglobulins, Intravenous | 1 | 1993 | 652 | 0.000 |
Why?
|
| Breast Neoplasms | 1 | 1995 | 20824 | 0.000 |
Why?
|
| Recombinant Fusion Proteins | 1 | 1996 | 3773 | 0.000 |
Why?
|
| Binding Sites | 1 | 1996 | 6111 | 0.000 |
Why?
|
| Survival Rate | 1 | 2001 | 12788 | 0.000 |
Why?
|
| Heparin | 1 | 1993 | 1637 | 0.000 |
Why?
|
| Fetus | 1 | 1993 | 1880 | 0.000 |
Why?
|
| Base Sequence | 1 | 1996 | 12797 | 0.000 |
Why?
|
| Fertilization in Vitro | 1 | 1993 | 1284 | 0.000 |
Why?
|
| Endometriosis | 1 | 1993 | 839 | 0.000 |
Why?
|
| Amino Acid Sequence | 1 | 1996 | 13814 | 0.000 |
Why?
|
| Molecular Sequence Data | 1 | 1996 | 18111 | 0.000 |
Why?
|
| Histones | 1 | 1993 | 2598 | 0.000 |
Why?
|
| Hypertension | 1 | 1993 | 8479 | 0.000 |
Why?
|
| Mice | 1 | 1993 | 81201 | 0.000 |
Why?
|